Objective information on common medication classes for ADPKD patients, monitoring requirements, nephrotoxicity warnings, and TCM evidence boundaries.
β Important Boundaries
This page provides only objective, class-level medication information. It does not provide individualized prescriptions, dosing, substitution recommendations, or self-treatment advice. Whether to use, how to use, and when to adjust must be decided by your nephrologist or pharmacist based on your kidney function, comorbidities, and current medications. Do not start or stop medications based on this page alone.
Filters only visible content on this page. No information is uploaded.
π« 1. ADPKD-Directed Therapy
The only medication currently recommended by guidelines to slow cyst growth and kidney function decline in ADPKD is tolvaptan. Whether it is appropriate must be determined by a nephrologist based on Mayo Imaging Classification/RAAP risk stratification, liver function, eGFR, and thirst tolerance.
Hypertension is common and early in ADPKD. Guidelines generally recommend ACEI/ARB as first-line, especially with proteinuria. CCB or diuretics may be added by your doctor when not at target or not tolerated. Target BP is typically < 130/80 mmHg, individualized by your doctor.
ACEI / ARB
Evidence APrescriptionADPKD first-line BP
Class: Renin-angiotensin system inhibitors. ACEI inhibits angiotensin-converting enzyme; ARB blocks the AT1 receptor.
Representative generics: ACEI β enalapril, benazepril, ramipril; ARB β valsartan, losartan, irbesartan, telmisartan. For identification only, not a selection recommendation.
Mechanism: Lowers systemic blood pressure, reduces intraglomerular pressure, decreases proteinuria, may slow kidney function decline.
Monitoring & Common Adverse Effects
Monitoring: Check creatinine and potassium 1-2 weeks after starting or adjusting; then regularly. Transient mild creatinine rise (β€30%) is usually acceptable; significant rise needs physician evaluation.
Common adverse effects: Hyperkalemia, dry cough (ACEI), hypotension.
Not suitable for: Bilateral renal artery stenosis, severe hyperkalemia, pregnancy (teratogenic).
Do not self-combine: ACEI and ARB are generally not combined; combination with potassium-sparing diuretics requires physician assessment of hyperkalemia risk.
As eGFR declines, management of anemia, bone-mineral metabolism, electrolyte, and acid-base abnormalities may be needed. Whether to use, dosing, and monitoring are determined by your physician based on lab results.
Erythropoiesis-Stimulating Agents (ESA)
Evidence APrescription
Class: Erythropoietin and long-acting analogs (e.g., darbepoetin).
Mechanism: Supplements CKD-related EPO deficiency, stimulating bone marrow red blood cell production.
Typical scenario: Renal anemia (Hb typically < 100 g/L) with adequate iron stores, initiated by physician.
Monitoring & Common Adverse Effects
Monitoring: Hemoglobin, iron studies (ferritin, TSAT), blood pressure, thrombosis risk.
Target: Hb should not be too high (generally β€115-120 g/L); higher levels increase cardiovascular risk.
Note: Iron deficiency is usually corrected first; do not self-inject.
Mechanism: Binds dietary phosphate in the gut, reducing absorption.
Typical scenario: CKD G3b-G5 with hyperphosphatemia uncontrolled by diet.
Monitoring & Common Adverse Effects
Monitoring: Phosphorus, calcium, PTH.
Note: Long-term calcium-based binders may worsen vascular calcification; non-calcium binders preferred when hypercalcemic. Must be taken with meals and chewed.
Note: Allopurinol initiation can precipitate gout attacks; colchicine prophylaxis often needed. HLA-B*5801 carriers have high risk of severe cutaneous reactions to allopurinol.
Renal adjustment: Febuxostat cardiovascular risk has been noted; physician weighs risks.
Mechanism: Inhibits proximal tubular glucose reabsorption, lowering blood glucose while reducing intraglomerular pressure, decreasing proteinuria, and providing cardio-renal protection.
Typical scenario: CKD with proteinuria or heart failure, prescribed by physician within appropriate eGFR range; ADPKD use requires individual assessment.
Class: Ibuprofen, diclofenac, naproxen, meloxicam, celecoxib, etc.
Risk: Can cause afferent arteriole constriction, acute kidney injury, sodium-water retention, hyperkalemia, and worsened hypertension. Higher risk in CKD; "triple whammy" when combined with ACEI/ARB and diuretics.
Usage Guidance
Short-term, occasional use only β do not self-medicate long-term.
Inform your doctor of your kidney function and current BP medications before use.
Seek immediate care for oliguria, edema, or creatinine rise.
Do not combine two NSAIDs or stack with cold medications containing the same ingredients.
The following classes typically require physician dose adjustment or risk assessment when kidney function is reduced. Do not judge "safety" by drug name alone.
Contrast media: Iodinated contrast can cause contrast-associated AKI. Higher risk with low eGFR, diabetes, dehydration, concurrent NSAIDs/ACEI/ARB. Physician assesses hydration and dose before and after imaging.
Antibiotics: Vancomycin, aminoglycosides (gentamicin, etc.), some antivirals require eGFR-based dosing and drug-level monitoring.
πΏ 7. Chinese Patent Medicine & TCM Evidence Boundaries
β Important Boundaries
Chinese patent medicines lack high-quality evidence for shrinking cysts or replacing standard ADPKD treatment. This section only compiles regulatory information verifiable at the National Medical Products Administration (NMPA) and evidence boundaries β it does not constitute treatment recommendations. Inform your nephrologist and pharmacist before using any Chinese patent medicine, herbal decoction, or supplement to avoid interactions or kidney burden.
General Principles for TCM Use
Regulatory verification: Legitimate Chinese patent medicines can be verified at the NMPA for approval numbers, labels, and manufacturers. Do not use "secret formulas" without approval numbers.
Evidence stratification: TCM understanding of ADPKD is mostly based on syndrome differentiation theory and small-sample observations, evidence level typically C-D, not equivalent to RCT or guideline recommendations.
Cannot claim: Cannot claim to shrink cysts, lower creatinine as treatment, replace tolvaptan or antihypertensives, or reverse kidney failure.
Nephrotoxicity alert: Aristolochic acid-containing herbs (historically used as Aristolochia manshuriensis stem, Aristolochia fangchi, etc.) can cause irreversible kidney injury and urothelial cancer. Avoid herbs of unknown origin.
Interactions: TCM can interact with ACEI/ARB, diuretics, anticoagulants, and immunosuppressants β requires physician/pharmacist review.
Aristolochic acid-containing herbs: Historically caused aristolochic acid nephropathy and urothelial cancer. Some banned/replaced nationally, but unknown-source herbs, folk remedies, and weight-loss teas remain a risk.
Other cautions: Tripterygium wilfordii (immunosuppression, reproductive toxicity), cinnabar/realgar (heavy metal-containing), high-potassium diuretic herbs need physician assessment in CKD.
Do not: Do not use unapproved "ancestral secret formulas," do not long-term self-brew unknown herbs, do not treat supplements as therapy.
The following are interaction categories of particular concern for ADPKD/CKD patients. Specific interactions should be reviewed by your physician or pharmacist based on your complete medication list β do not self-assess.
ACEI/ARB + NSAIDs + diuretics ("triple whammy"): Additive risk of AKI and hyperkalemia β avoid self-combining.
Iodinated contrast + metformin: Metformin typically held before/after contrast β physician arranges.
TCM + prescription drugs: Any Chinese patent medicine, herbal decoction, or supplement combined with prescription drugs must be reviewed by physician/pharmacist first.
π When to Contact Your Doctor or Seek Emergency Care
Rash, edema, oliguria, dark urine, jaundice, or persistent vomiting after starting a new medication, TCM, or supplement.
Significant short-term creatinine rise, potassium abnormality, or major blood pressure fluctuation.
Any symptoms described in Emergency Signs (oliguria/anuria, severe flank pain with fever, worsening hematuria, difficulty breathing, altered consciousness).
Before planning pregnancy, surgery, imaging with contrast, or vaccination β physician must assess current medications.
Evidence level: AβD (per KDIGO standard) Limitations: This page is a class-level overview and does not cover all medications or individual situations. Drug indications, dosing, and interactions should be based on the label and your treating physician.